Introduction
============

Estrogen receptors (ERα and ERβ) control a range of physiological processes regulating the development and function of the female reproductive system as well as the maintenance of bone mass, and play protective roles in the cardiovascular and central nervous systems. ERs are also implicated in related pathologies such as breast and uterine cancers, osteoporosis and cardiovascular diseases ([@bib94], [@bib26], [@bib55]). Their roles in cancer development have led to the development and clinical use of small synthetic molecules that block either estrogen production (aromatase inhibitors) or estrogenic signaling (antiestrogens, AEs). AEs are steroids or steroid mimics that compete with endogenous estrogens ([Fig. 1A](#fig1){ref-type="fig"}) for binding to ERs and modify their activity as ligand-dependent transcriptional regulators ([@bib39], [@bib7]). However, some AEs, including tamoxifen and raloxifene, have complex patterns of activity in estrogen-responsive tissues, acting as so-called selective estrogen receptor modulators (SERMs). For instance, tamoxifen displays mostly antagonist activity in breast but has partial agonist activity in uterus and bones ([@bib134], [@bib60], [@bib96]). Figure 1Chemical structures of estrogen receptor agonists and antagonists. (A) The three most abundant circulating estrogens: estrone, 17β-estradiol and estriol. (B) Tamoxifen and its active derivatives, 4-hydroxytamoxifen and endoxifen, as well as tamoxifen-derived SERMs. (C) Antiestrogens with different steroid-like backbones and a side chain containing a tertiary amine: SERM raloxifene and related compounds arzoxifene and bazedoxifene, as well as acolbifene. (D) Pure antiestrogens with steroid backbones and long side chains. (E) SERDs with steroid-like backbones and a side chain containing an acrylic acid.

On the other hand, fulvestrant and related compounds are devoid of partial agonist activity and behave as pure AEs. The lack of systematic cross-resistance to pure AEs observed in tumors that have progressed under treatment with tamoxifen, or in cell lines that have gained the capacity to grow in the presence of SERMs, suggested that pure AEs and SERMs have different mechanisms of action ([@bib47], [@bib2]). Properties characteristic of pure AEs include induction of accelerated turnover of ERα via increased proteasomal degradation; hence, their designation as selective estrogen receptor downregulators (SERDs) ([@bib84]). Although fulvestrant has failed to demonstrate improved responses in first-line treatment compared with SERMs or aromatase inhibitors ([@bib48]), a better understanding of the mechanisms of action of pure AEs is important in view of the development and current clinical testing of several new SERDs with improved oral bioavailability compared with fulvestrant ([@bib18], [@bib84]). This review focuses on what is known and what remains to be determined about the mechanisms of action of AEs, with an emphasis on properties specific to pure AEs.

SERMs vs SERDs: two separate classes of antiestrogens?
======================================================

Tamoxifen and next-generation SERMs
-----------------------------------

Selective ER modulators (SERMs) (e.g., tamoxifen, raloxifene and analogues, [Fig. 1B](#fig1){ref-type="fig"} and [C](#fig1){ref-type="fig"}) have earned their name due to their tissue- and gene-specific activities. Tamoxifen, the first clinically approved SERM and the standard of care for the adjuvant treatment of all stages of primary breast tumors to this day ([@bib58], [@bib2], [@bib83]), has antagonist effects on breast cancer cell proliferation but has an estrogen-like action in bone in patients and in animal models, where it helps maintain bone mineral density in postmenopausal women, and has favorable agonist effects on lipid profiles ([@bib127], [@bib134], [@bib74],[@bib75]). In addition, tamoxifen and its active metabolite 4-hydroxytamoxifen have marked estrogenic activity in the uterus of ovariectomized rats or mice and are associated with an increased risk of endometrial cancer in the clinic ([@bib82], [@bib24]). Increases in mouse uterine wet weight induced by tamoxifen were dependent on the expression of ERα in the uterus ([@bib62]). In addition, although tamoxifen treatment has proven effective in reducing the risk of breast tumor progression, resistance to tamoxifen develops in a significant proportion of primary tumors and in most patients with metastatic cancer, without loss of ERα expression in the majority of cases ([@bib58], [@bib91]). Observation of remissions after tamoxifen withdrawal or switch to aromatase inhibitors or pure AEs has suggested that ER signaling remains active in the presence of tamoxifen in some tamoxifen-resistant breast tumors ([@bib2], [@bib84]).

Tamoxifen analogues ([Fig. 1B](#fig1){ref-type="fig"}) have been developed to increase treatment efficacy and decrease the negative side effects of tamoxifen, including the increase in the incidence of endometrial cancer and thromboembolic events and the generation of DNA adducts (see [@bib83] for an in-depth review of the pharmacological properties of tamoxifen analogues). For example, toremifene ([Fig. 1B](#fig1){ref-type="fig"}) is a chloride derivative of tamoxifen that has been reported to have lower estrogenic and genotoxic effects than tamoxifen. Similarly, tamoxifen derivatives droloxifene (3-hydroxytamoxifen), which has increased affinity for ERα but a reduced half-life, and idoxifene, which is metabolized more slowly than tamoxifen due to the addition of an iodine at position 4 and has a modified side chain with a pyrrolidino group ([Fig. 1B](#fig1){ref-type="fig"}), were both found to have decreased uterotrophic activity. Lasofoxifene, a tamoxifen analogue with a modified polycyclic core structure and a side chain similar to that of idoxifene ([Fig. 1B](#fig1){ref-type="fig"}), is an antagonist in both breast and uterus. All these compounds possess a strong agonist activity in bones. However, these drugs are neither more efficacious than tamoxifen for breast cancer treatment nor do they circumvent resistance to tamoxifen in patients ([@bib47], [@bib2], [@bib83]).

Raloxifene, a SERM with a benzothiophene backbone ([Fig. 1C](#fig1){ref-type="fig"}) that is prescribed for prevention of osteoporosis and associated with favorable agonist-like action on lipid metabolism, has only low activity in the uterus of ovariectomized rodents ([@bib12]). Raloxifene was shown to retain 76% of the effectiveness of tamoxifen at reducing invasive breast cancer incidence with a significantly lower incidence of endometrial cancer in the Study of Tamoxifen and Raloxifen (STAR) prevention trial ([@bib131]), but is not effective in patients resistant to tamoxifen ([@bib2], [@bib83]). Further, the raloxifene analogue arzoxifene ([Fig. 1C](#fig1){ref-type="fig"}), despite being more potent than tamoxifen or 4-hydroxytamoxifen on inhibition of human mammary carcinoma cell proliferation and on decreasing rat uterine wet weight ([@bib102], [@bib122]), was not as efficacious as tamoxifen in a comparative phase III clinical trial ([@bib27]) and was partially cross-resistant with tamoxifen in xenograft models ([@bib113]).

Fulvestrant and other SERDs with long side chains
-------------------------------------------------

Another class of AEs developed to minimize partial agonist activity and address resistance issues ([@bib132]) includes steroidal compounds with long side chains such as ICI 164,384, ICI 182,780 (fulvestrant/Faslodex) and RU 58,668 ([Fig. 1D](#fig1){ref-type="fig"}). These compounds were initially referred to as pure AEs due to their lack of partial agonist activity in pre-clinical models including in breast and endometrial cell lines ([@bib15], [@bib133], [@bib129], [@bib8]). Moreover, ICI 182,780 was able to suppress the agonist activity of estradiol and tamoxifen in the uterus of ovariectomized rodents ([@bib133]). ICI 182,780 also does not have an agonist effect on bone cells *in vitro* and in animal models ([@bib35], [@bib21], [@bib103]). Although ICI 182,780 is not orally bioavailable, its subcutaneous injection (5 mg/week) suppressed the growth of MCF-7 xenografts in mice longer than tamoxifen (500 μg/day s.c.) ([@bib99]). Further, RU 58,668 can cause long-term regression of MCF-7 xenografts ([@bib129]). Importantly, cross-resistance between ICI 182,780 and tamoxifen was not observed in cultured cell lines or in xenograft models ([@bib51], [@bib78], [@bib77]); further, fulvestrant was comparable to aromatase inhibitors in clinical efficacy in postmenopausal women having progressed on tamoxifen therapy ([@bib50], [@bib100]). These data suggested that pure AEs and SERMs act via different molecular mechanisms. Indeed, although 4-hydroxytamoxifen increases overall ERα protein levels, pure AEs accelerate ERα turnover through the ubiquitin--proteasome pathway in ERα-positive breast cancer cells and in extracts of rodent uterine tissues, hence, their designation as SERDs ([@bib36], [@bib23], [@bib30], [@bib145]). However, despite the pure antiestrogenic character of fulvestrant, it did not compare advantageously with tamoxifen when used as a first-line therapy for advanced or metastatic breast cancer ([@bib48], [@bib47]). The poor pharmacokinetic properties of ICI 182,780 may limit its effectiveness in the clinic; indeed, increasing monthly intra-muscular injections of fulvestrant from 250 mg to 500 mg led to significant gains in overall survival in metastatic patients having recurred or progressed after prior endocrine therapy in the CONFIRM study and resulted in subsequent adoption of this regimen in the clinic ([@bib28], [@bib29], [@bib109]). Further development of pure AEs has focused on gains in affinity and oral bioavailability. For instance, fulvestrant analogues ZK-703 and ZK-253 ([Fig. 1D](#fig1){ref-type="fig"}) were shown to inhibit growth of ER+ xenografts, including tamoxifen-resistant tumors, more efficiently than ICI 182,780; interestingly, compound ZK-253 demonstrated increased oral bioavailability in these models ([@bib46]).

SERM derivatives with SERD activity
-----------------------------------

Interestingly, compounds derived from tamoxifen such as GW7604 and analogues ([Fig. 1E](#fig1){ref-type="fig"}) can also induce ERα degradation ([@bib146], [@bib10]) and may prove to be promising clinical candidates as they have better oral bioavailability than ICI 182,780 ([@bib84]). Of note, GDC-0810 induced degradation of ERα with similar potency and efficacy as ICI 182,780 and was effective at suppressing growth of both tamoxifen-sensitive and -resistant xenografts ([@bib63]). GDC-0810 and a structural analogue (AZD9496) are undergoing evaluation in currently accruing clinical trials (see <https://clinicaltrials.gov/ct2/results?term=GDC-0810&Search=Search>; accessed Aug. 15, 2016). In addition, although raloxifene induces a slight increase in ERα turnover, raloxifene-related bazedoxifene ([Fig. 1C](#fig1){ref-type="fig"}) is more efficacious in this respect, correlating with fuller antiestrogenic properties. Bazedoxifene is indeed more effective than other SERMs (tamoxifen, raloxifene and lasofoxifene) at inhibiting gene expression in MCF-7 cells and can inhibit tamoxifen-resistant xenograft growth ([@bib137]). Bazedoxifene is currently prescribed for the prevention and treatment of osteoporosis, as bazedoxifene and raloxifene had similar impacts on bone mineral density and lipid profiles in a 24-month randomized clinical study ([@bib89]) and on ER signaling in bone ([@bib107]). A phase I/II clinical trial currently investigates the combination of the CDK4/6 inhibitor Palbociclib and bazedoxifene in stage IV breast cancer patients (see <https://clinicaltrials.gov/ct2/show/Nbib2448771>; accessed Aug. 15, 2016). Similarly, although EM-800 and its active metabolite EM-652 (acolbifene, [Fig. 1C](#fig1){ref-type="fig"}) are SERMs, displaying agonist activity in bone and on lipid metabolism but limited estrogenic activity in the uterus ([@bib49]), EM-800 induces accelerated turnover of ERα compared to tamoxifen, albeit to a lesser extent than raloxifene ([@bib147]).

Therefore, it appears that AEs present a spectrum of SERD activity, with tamoxifen at one end being devoid of ERα down-regulating capacity, whereas some SERM analogues reduce ERα protein levels to variable levels (EM-652, raloxifene, bazedoxifene, GW7604 and GDC-0810). Finally, pure AEs with long side chains are associated with strong SERD activity (ICI 164,384, ICI 182,780, ZK-253, ZK-703 and RU 58,668).

Molecular determinants of antiestrogenicity
===========================================

Structural basis for AF2 transcriptional activity
-------------------------------------------------

ERs share with other nuclear receptors (NRs) a common structure with a central DNA-binding domain (DBD) flanked by two transcriptional activation function domains, AF1 and AF2, the latter overlapping with the ligand-binding domain (LBD) ([Fig. 2A](#fig2){ref-type="fig"}). Ligand binding regulates NR conformation, nuclear localization, binding to specific response elements and recruitment of coactivators/corepressors ([@bib90], [@bib139], [@bib4], [@bib111], [@bib144]). Although unstable in the absence of ligand, the LBD can be crystallized in the presence of agonists (estradiol, E2), revealing folding into an α-helical sandwich structure characteristic of the nuclear receptor superfamily. The ligand-binding pocket is formed within the hydrophobic core of the LBD below the central layer of helices ([Fig. 2B](#fig2){ref-type="fig"}) and is lined by hydrophobic residues from H3, H6, H8, H11, H12 and the S1/S2 hairpin ([@bib16]). Charged amino acids stabilize the binding of agonists and antagonists by interacting with hydroxyl groups located at either end of the estrogenic steroidal backbone (Glu353, Arg394 and His524 in hERα; Glu260, Arg301 and His430 in rERβ). Agonist (E2) binding stabilizes a conformation of the ligand-binding domain where H12 folds tightly back on top of the ligand-binding pocket ([Fig. 2B](#fig2){ref-type="fig"}), positioning a set of amino acids (Asp538, Leu539, Glu542 and Met543) adequately for coactivator peptide interaction ([@bib16], [@bib117], [@bib138]). Figure 2ERα structure, post-translational modifications and conformational changes induced by different ligands. (A) Schematic representation of ERα structure. AF1/AF2: activation function 1/2; DBD: DNA-Binding Domain; NLS: Nuclear Localization Signal; LBD: Ligand-Binding Domain. SUMOylation sites identified by mass spectrometry in the presence of ICI 182,780 are indicated in purple. Residues phosphorylated in the presence of antiestrogens or implicated in the modulation of sensitivity to antiestrogen treatment are indicated in orange. (B) LBD ERα -- estradiol (E2) -- TIF2 NR box 3 complex ([@bib138]); (C) LBD ERα -- 4-hydroxytamoxifen complex (OHT) ([@bib117]); (D) LBD ERβ -- ICI 164,384 complex ([@bib106]); (E) LBD ERα -- GW5638 complex ([@bib148]). Representations were generated using PyMOL. Helix 12 is highlighted in red and each ligand is shown in green. The α-helical TIF2 coactivator motif is shown in gold.

Impact of SERMs on AF2 activity
-------------------------------

AEs are steroid or steroid-like (e.g. triphenylethylene or benzothiophene backbones of tamoxifen or raloxifene, respectively) molecules that bind to the ERα LBD in a manner similar to estradiol. Bulky side chains attached at positions 7α or 11β of a steroid core or at equivalent positions on a steroid-like skeleton are responsible for antiestrogenicity ([@bib58]). They project out of the ligand-binding cavity between helices 3 and 11 and prevent the positioning of H12 over the ligand-binding cavity via steric clashes. This is achieved through different structural rearrangements depending on the length and composition of the AE side chain.

Several SERMs including tamoxifen and raloxifene and analogues ([Fig. 1B](#fig1){ref-type="fig"} and [C](#fig1){ref-type="fig"}) contain alkylaminoethoxy side chains with different tertiary amine substituents. Steric clashes involving the dimethylamino group of tamoxifen or the piperidyl group of raloxifene favor the repositioning of H12 to the coactivator-binding groove ([@bib16], [@bib117]) ([Fig. 2C](#fig2){ref-type="fig"} 4-hydroxytamoxifen, OHT). Hydrophobic amino acids in H12 (Leu540, Met543 and Leu544) interact with the coactivator-binding groove in a manner similar to amphipathic coactivator LXXLL motifs ([@bib117], [@bib105]). Replacing the nitrogen in the raloxifene side chain with a carbon or a non-basic nitrogen atom abolished the antagonist activity of raloxifene derivatives in uterine wet weight assays ([@bib37]) and induced ER-dependent transcription in stably transfected MDA-MB-231 cells ([@bib69]). Crystallographic studies have revealed that the tertiary amine of raloxifene forms a hydrogen bond with Asp351 in H3 of the ERα LBD ([Fig. 3](#fig3){ref-type="fig"}) ([@bib16]). Mutating Asp351 to Glu converted raloxifene, which behaves as a pure antagonist in transiently transfected HepG2 cells, into a partial agonist resembling tamoxifen ([@bib25]). Interaction of the tertiary amine with Asp351 appears weaker in tamoxifen than that in raloxifene (3.8 vs 2.8 Å, [Fig. 3](#fig3){ref-type="fig"}) and the D351E mutation had little effect on the partial agonist activity of tamoxifen in HepG2 cells. Exchanging the tertiary amine group in tamoxifen for that of idoxifene led to loss of partial agonism with wt ERα, suggesting optimized interaction with Asp351. Conversely, partial agonism of this molecule was restored to levels comparable with those of tamoxifen by the D351E mutation, similar to observations with raloxifene ([@bib25]). Mutation D351G abrogated induction of expression of the estrogen target gene *TGFA* by tamoxifen in transfected MDA-MB-231 cells ([@bib79]), and mutation D351A abolished partial activity of ERα on a reporter gene in the presence of tamoxifen in HepG2 cells ([@bib25]), consistent with a role of Asp351 in mediating the partial agonist activity of SERMs in the absence of optimal interaction with their side chain tertiary amines. Figure 3Role of Asp351 in the different activity of tamoxifen and raloxifene. Overlay of X-ray structures of 4-hydroxytamoxifen (green) and raloxifene (aqua) bound to ERα (data from [@bib117] and [@bib16], respectively). The distance from Asp351 to the dimethylamine in 4-hydroxytamoxifen (3.8 Å) is 1.0 Å longer than to the piperidine in raloxifene.

Impact of pure AEs on AF2 activity
----------------------------------

First-generation pure AEs such as fulvestrant have longer side chains than SERMs ([Fig. 1D](#fig1){ref-type="fig"}). A crystal structure of ICI 164,384 with the rat ERβ LBD reveals that the long side chain at position 7α exits the ligand-binding cavity in a manner similar to that of the SERM side chains, but bends by 90 degrees at its fifth carbon, hugging the surface of the LBD and interacting with the coactivator-binding groove ([@bib106]) ([Fig. 2D](#fig2){ref-type="fig"}). The terminal hydrophobic n-butyl group of ICI 164,384 fits into a pocket formed by the side chains of Leu261, Met264, Ile265 and Leu286 in the coactivator-binding groove of rat ERβ (Leu354, Met357, Ile358 and Leu379 in human ERα). This interaction displaces H12 from its position in the binding groove observed in structures with 4-hydroxytamoxifen (OHT) and raloxifene ([Fig. 2C](#fig2){ref-type="fig"}) ([@bib16], [@bib117]). H12 is disordered in the crystal structure with ICI 164,384, suggestive of high mobility ([@bib106]). Although this structure was obtained with ERβ, and binding of ICI 164,384 does not induce accelerated degradation of this receptor ([@bib104]), the relevance of side chain interaction with the coactivator-binding groove of ERα (lined with amino acids conserved with ERβ) for pure antiestrogenicity has been supported by the analysis of ICI 164,384 derivatives with variable side chain lengths. Pure antiestrogenicity was optimal with side chain lengths of 15--19 atoms in a reporter assay in HepG2 cells transiently transfected with ERα, whereas the addition of shorter side chains (13 or 14 carbons side chains) resulted either in agonist or SERM activity ([@bib44], [@bib45]). Molecular modeling of these ICI 164,384 derivatives in complex with the ERβ LBD suggests that pure antiestrogenicity is associated with chain lengths long enough to reach the coactivator-binding groove ([Fig. 4](#fig4){ref-type="fig"} and [Video 1](#SM1){ref-type="supplementary-material"}). This is also compatible with the observed importance of the hydrophobicity of the terminal substituents for pure antiestrogenicity in steroidal derivatives. ICI 182,780, with a penta fluoropentyl terminal substituent, showed increased potency and efficacy in growth inhibition compared with ICI 164,384 in both cell and animal models of human breast cancer ([@bib133]). Figure 4Models of ICI 164,384 and derivatives bound to ERβ. (A) ICI 164,384 (X = CH~2~, *n* = 9, R = C~4~H~9~); (B) a 13-atom side chain (X = S, *n* = 8, R = CH~3~); (C) a 15-atom side chain (X = S, *n* = 8, R = C~3~H~7~); (D) a 19-atom side chain (X = S, *n* = 8, R = C~7~H~15~); docking was performed using the Glide software as previously described ([@bib44]).

Animation of the models of ICI 164,384 derivatives with 13 and 15-atom side chains bound to ERβ (corresponding to [Fig. 4B](#fig4){ref-type="fig"} and [C](#fig4){ref-type="fig"}). View Video 1 at <http://movie-usa.glencoesoftware.com/video/10.1530/JME-16-0024/video-1>.

Download Video 1

The side chain of ICI 164,384 creates steric clashes with H12 in the agonist conformation at amino acids Leu540 and Met543. Furthermore, it leads to steric clashes with Leu536, and to a lesser extent Leu540, when H12 is positioned in the coactivator-binding groove. Ala mutation of these residues increased transcriptional activity of ERα in the presence of pure AEs ([@bib80], [@bib95], [@bib76], [@bib6]), presumably by reducing steric clashes with H12.

Although the antiestrogenicity of ICI 182,780 is not affected by Asp351 mutations ([@bib25]), introduction of a tertiary amine in the ICI 182,780 side chain was associated with improved efficacy of compounds ZK-703 and ZK-253 at preventing growth of mouse xenografts from estrogen-sensitive and tamoxifen-resistant breast cancer lines ([@bib46]). Whether interaction with Asp351 is important for the improved performance of these compounds remains however to be assessed.

Molecular basis for SERD activity in SERM derivatives
-----------------------------------------------------

Alterations in the shorter side chains of SERM derivatives have also been observed to result in partial or full SERD activity. Bazedoxifene's overall structure is similar to that of raloxifene and differs by having a bulkier heterocyclic amine ring (azepane instead of piperidine ring, [Fig. 1C](#fig1){ref-type="fig"}), which may result in increased steric hindrance with H12. In addition, GW5638 (pro-drug of GW7604) is a tamoxifen analogue in which the dimethylaminoethoxy group is replaced by an acrylic acid side chain ([Fig. 1E](#fig1){ref-type="fig"}). The carboxylate group in the GW5638 side chain, in its protonated state, forms hydrogen bonds with Asp351 and the peptidic backbone of H12. This results in a distinct conformation of H12 ([Fig. 2E](#fig2){ref-type="fig"}) with relocation of the side chains of hydrophobic residues (Leu536, Leu539, Leu540 and Met543) toward the protein exterior, increasing the exposed hydrophobic surface of H12 compared with the ERα -- 4-hydroxytamoxifen structure while preserving interaction in the coactivator-binding groove ([@bib148]).

Thus, pure antiestrogenicity appears associated with exposure of hydrophobic amino acids of H12 to the solvent irrespective of the precise positioning of H12 in crystal structures (occupancy of the coactivator-binding groove in GW7604, but not in ICI 164,384). How these structural features result in altered protein--protein interactions and in a decreased stability of ERα is still imperfectly understood.

Impact of AE-induced ERα conformation on cofactor recruitment and transcriptional activation
============================================================================================

Gene expression profiles of SERMs and SERDs in breast and uterine cancer cell models
------------------------------------------------------------------------------------

The characterization of gene expression profiles in the presence of AEs in breast and uterine cancer cells has indicated that SERMs display partial agonist activity in a gene-specific manner, while SERDs achieve a more complete inhibition of estrogen signaling. Indeed, tamoxifen regulates transcription of subsets of estrogen target genes in endometrial carcinoma cell lines (Ishikawa, ECC-1) and also in ER+ breast cancer cell lines (MCF-7, ZR-75-1), in addition to altering expression of sets of genes apparently not regulated by estradiol via mechanisms that remain to be clarified ([@bib116], [@bib34], [@bib112], [@bib20], [@bib135], [@bib124]). ICI 182,780 functions as a pure antagonist for genes partially activated by SERMs in MCF-7 cells, whereas raloxifene has an intermediate profile, its agonist activity mostly overlapping with that of tamoxifen. On the other hand, bazedoxifene exhibits a SERD-like profile ([@bib34], [@bib137]). ChIP-seq experiments in MCF-7 cells have shown binding of ERα to a significant number of estrogen target sites after 1 h of ICI 182,780 treatment ([@bib143]); in contrast, association of ERα with DNA was not observed 3 h after addition of ICI 182,780 in another study ([@bib108]), possibly due to receptor degradation. It will be of interest to examine whether release of ERα from DNA is a general property of SERDs and correlates with the degradation of the receptor in the presence of these ligands, or with earlier events such as protein modification and/or altered cofactor recruitment.

Impact of SERMs and SERDs on coactivator recruitment to ERα
-----------------------------------------------------------

ERs recruit a plethora of cofactors in an agonist-dependent manner via both their N-terminal and C-terminal activation function regions (AF1 and AF2 respectively), including histone modifiers, chromatin remodeling complexes and components of the transcriptional machinery ([@bib120], [@bib40]); (see also a list of known nuclear receptor coregulators at <https://www.nursa.org/nursa/molecules/index.jsf>, accessed on Aug. 15, 2016). The various ERα LBD conformations induced by different AEs affect protein--protein interaction interfaces ([@bib137]) and result in altered recruitment of cofactors both in solution and on DNA.

Among the coactivators interacting directly or indirectly with AF2 of the estradiol-bound ERα are the histone acetyl transferases NCOA1/2/3 (SRC-1/2/3), CBP/p300 and the histone methyl transferases CARM1, PRMT1 ([@bib120], [@bib40], [@bib56]). In endometrial Ishikawa and ECC-1 cell lines, NCOA1 is recruited selectively to promoters of genes stimulated by tamoxifen, but not raloxifene; repressing NCOA1 expression in Ishikawa cells inhibits the partial agonist activity of tamoxifen on those target genes ([@bib116]). Conversely, overexpressing NCOA1 in MCF-7 cells confers agonist activity to tamoxifen on genes it otherwise antagonizes, suggesting that differential expression of NCOA1 in breast and uterine cells underlies tissue-specific transcriptional regulation by tamoxifen ([@bib116]). In addition, overexpressing the coactivators NCOA2 and p300 in ERα-transfected HeLa cells strongly increased the partial agonism of tamoxifen on an ERE-TK-Luc reporter vector, had a moderate effect for raloxifene and barely increased reporter vector activity in the presence of ICI 182,780 ([@bib140]), suggesting that several coactivators may contribute to the partial agonist activity of SERMs in a cell- and gene-specific manner. Finally, NCOA3 (AIB1) is amplified in 11% of breast tumors and is associated with a worse prognosis in ER+, but also ER− tumors ([@bib17]); its tumorigenic potential may therefore result from a role as coactivator of other transcription factors, such as E2F1 ([@bib73]).

The partial agonist activity of tamoxifen, and to a lower degree of raloxifene, has been linked with activity of the ligand-independent AF1 function of ERα ([Fig. 2A](#fig2){ref-type="fig"}) in different cell and promoter contexts ([@bib11], [@bib128], [@bib97], [@bib141], [@bib140], [@bib9], [@bib88]). For instance, the AF1 domain of ERα was necessary to observe agonist effects of tamoxifen in a human endometrial cancer cell line (HEC1 cells) ([@bib85]). Similarly, swapping the AF1 domain of ERα with the corresponding region in ERβ abrogated ERα transcriptional activity in the presence of tamoxifen in U2OS cells, supporting the role of this region in the partial agonism of tamoxifen ([@bib150]). These observations can be correlated to the capacity of ERα, but not of ERβ, to recruit NCOA1 via its AF1 region in the presence of tamoxifen ([@bib141], [@bib87]). It remains unclear whether ERα can also recruit other cofactors in the presence of tamoxifen via its AF1 region, such as the p68 RNA helicase and the RNA molecule SRA ([@bib64], [@bib52]), and how cofactor recruitment via AF1 is enabled by the specific conformation of AF2 in tamoxifen-liganded ERα ([@bib5]).

Impact of SERMs and SERDs on corepressor recruitment
----------------------------------------------------

In the presence of tamoxifen, ERα recruits the corepressors NCOR1 (N-CoR) and NCOR2 (SMRT) at repressed estrogen target genes in MCF-7 cells, but not at genes upregulated by tamoxifen in Ishikawa cells; siRNA knockdown of these corepressors increases ER target gene expression and MCF-7 cell proliferation in the presence of tamoxifen *in vitro* and in xenograft models ([@bib65], [@bib116], [@bib59]). In addition, overexpression of corepressor NCOR2 suppresses the partial agonist activity of tamoxifen in HepG2 cells ([@bib119]). ChIP time-course experiments linked the recruitment of NCOR1/HDAC3 and the NuRD/HDAC1 complexes by tamoxifen-bound ERα with subsequent hypoacetylation of histones and loss of RNA Polymerase II binding at the *TFF1* and *MYC* promoters in MCF-7 cells ([@bib68]).

ICI 182,780-bound ERα can recruit the C-terminal fragment of NCOR1 more efficiently than with raloxifene or tamoxifen, as shown by immunoprecipitation experiments in transfected HeLa cells ([@bib140]). However, the exact mechanisms of corepressor recruitment in the presence of SERMs and SERDs remain to be determined. Co-crystallization of a corepressor-NR box (CoRNR box, consensus LXXXIXXXL) peptide with the ERα LBD in the presence of raloxifene was only possible upon deletion of H12 ([@bib42]). In this structure, the CoRNR^ER^ peptide occupies the AF2 groove between H3 and H5, the N-terminus of the peptide being packed against the raloxifene side chain. Whether the different conformations of H12 in SERD- vs SERM-bound ERα are responsible for the increased recruitment of corepressors in the presence of SERDs needs to be investigated. Of note, the N-terminal receptor-interacting domain (nRID) of the corepressors NCOR1 and NCOR2 was also shown to interact with ERα via its DBD ([@bib130]), although this interaction did not appear to be ligand regulated.

Existence of SERM/SERD-specific cofactors
-----------------------------------------

Characterization of proteins interacting with a TAP-tagged version of ERα in MCF-7 cells indicated that the majority of interactors are ligand-specific, the interactomes of ERα bound to raloxifene and tamoxifen overlapping only partially with each other and with that of ERα bound to estradiol and being distinct from that obtained in the presence of ICI 182,780 ([@bib22]). In addition, ICI 182,780 was shown to selectively induce interaction of ERα, but not ERβ, with luminal cytokeratins CK8/CK18, a property that correlated with ERα insolubility and increased turnover ([@bib72], [@bib71]). Finally, selective recruitment of Ubi and SUMO E3 ligases in the presence of SERDs is likely in view of the patterns of receptor modification induced by SERD binding (see below). The interaction profiles of SERMs with partial SERD activity remain to be investigated, and it will be of interest to determine whether these molecules elicit interactions with some of the ICI 182,780-specific ERα interactors.

Parameters affecting cofactor recruitment by ERs in the presence of AEs
-----------------------------------------------------------------------

Although cofactor recruitment is primarily determined by the conformation of the ER LBD induced by ligand binding, the relative expression levels of coactivators and corepressors in different tissues likely account for tissue-specific partial agonist activity (see above). In addition, variation in cofactor expression levels during tumorigenesis may contribute to resistance to AEs ([@bib98], [@bib121]). Promoter context is expected to affect partial agonist activity in a gene-specific manner either due to cofactor interaction with other DNA-bound transcription factors or to allosteric effects of the DNA sequence on the receptor conformation ([@bib120], [@bib56]). In addition, the relative expression levels of ERα and ERβ, the activity of signaling pathways leading to post-translational modifications of the receptors and/or their coregulators, and the extent of ERα downregulation may all contribute to the specific activity profiles of AEs ([@bib120], [@bib83]).

Role of post-translational modifications of ERα by Ubi-like molecules in pure antiestrogenicity
===============================================================================================

Post-translational modifications (PTMs) targeting ERs as well as their cofactors in response to ligand binding likely play a role in modulating cofactor recruitment. Improvements in mass spectrometry have allowed the identification of PTM sites throughout ERα, including phosphorylation, methylation and acetylation. For example, phosphorylation of Ser104, 106 and 118 in the AF1 region and of Ser305 in the E region might be involved in resistance to tamoxifen ([@bib66] and refs within; [Fig. 2A](#fig2){ref-type="fig"}). Ser104, 106 and 118 are also phosphorylated in the presence of pure AEs ([@bib3], [@bib125]), but the possible impact of these modifications on transcriptional downregulation by SERDs remains to be investigated. In addition, dephosphorylation of Tyr537 ([Fig. 2A](#fig2){ref-type="fig"}) by the H1 protein-tyrosine phosphatase was observed to sensitize MCF-7 breast cancer cells to both SERMs and ICI 182,780 ([@bib123]). Finally, phosphoresidues pS167, pS282, pS576 and pS578 were detected in the presence of ICI 182,780 by mass spectrometry ([@bib44]) ([Fig. 2A](#fig2){ref-type="fig"}), but their function is currently unknown. Other types of modifications of ERα, which include acetylation, methylation, ubiquitination and SUMOylation ([@bib7], [@bib66]), may also affect the sensitivity of breast cancer cells to AEs.

Induction of ERα ubiquitination by SERDs
----------------------------------------

SERDs (ICI 182,780, RU 58,668 and GW7604) accelerate ERα degradation in uterine and breast cancer cell lines. Degradation takes place with faster kinetics than that in the presence of agonists in MCF-7 cells. Although 4-hydroxytamoxifen stabilizes ERα protein levels ([@bib145], [@bib76], [@bib61], [@bib44]), decreased steady-state levels of ERα were observed to variable extents in the presence of endoxifen (a tamoxifen metabolite), raloxifene and bazedoxifene. However, none of these AEs were as efficacious as the pure AE ICI 182,780 ([@bib137]). Affinity purification of ERα modified by tagged ubiquitin showed that ICI 182,780 triggers a 2-fold enhancement of ERα ubiquitination compared with basal levels ([@bib145]). Agonists induce or are permissive for recruitment of several E3 ubiquitin ligases, such as E6-AP, CHIP, MDM2, BRCA1/BARD1, EFP/TRIM25, SPOP, RBCK1, CUEDC2, SKP2, VHL and RNF31 by ERα ([@bib43] and refs within); some of these proteins are recruited to DNA and can act as ERα coactivators ([@bib70], [@bib108]). However, E3 ligases recruited in the presence of SERDs still need to be characterized.

Mechanisms of degradation appear to differ in the presence of AEs and estradiol. Inhibition of transcription by α-amanitin or other inhibitors prevents the induction of ERα turnover by agonists but not by ICI 182,780 ([@bib108]). In addition, cycloheximide treatment and several kinase inhibitors (PKA, PI3K) partially blocked the induction of ERα protein turnover by estradiol but not pure AEs ([@bib13], [@bib14], [@bib115], [@bib81]). Furthermore, overexpression of ERα in breast cancer cells can saturate the degradation process in the presence of SERDs, without affecting turnover in the presence of agonists ([@bib136]). Finally, removal or mutation of the nuclear localization signal (NLS) in ERα, resulting in cytoplasmic localization of the receptor, abolished degradation in the presence of ICI 182,780 but not estradiol, while adding back the endogenous NLS to the N-terminus of ERα partially restored the degradation of ERα in the presence of ICI 182,780 ([@bib19]). In spite of the above-mentioned differences between degradation mechanisms in the presence of estradiol and SERDs, the Neddylation pathway, which resembles the ubiquitination cascade and cooperates with it for induction of ubiquitination, appears to be important for both estradiol- and ICI 182,780-induced degradation ([@bib32]). Mapping of residues affected by polyubiquitination in the presence of SERDs and identification of E3 ligases and deubiquitinases controlling receptor modification by the ubiquitin system should clarify the similitudes and differences between the mechanisms of receptor degradation in the presence of SERDs vs agonists.

Induction of ERα SUMOylation by SERDs
-------------------------------------

Although induction of ERα degradation is expected to contribute to pure antiestrogenicity, saturating the degradation process by overexpressing ERα did not appear to affect the capacity of SERDs (bazedoxifene, ICI 182,780 and GW7604) to act as AEs in MCF-7 cells ([@bib136]). Further, although the steady-state levels of transfected ERα were not decreased but rather increased in the presence of ICI 182,780 in HepG2 cells, ICI 182,780 still acted as an inverse agonist in these cells, whereas tamoxifen had partial agonist activity ([@bib76], [@bib44]). This suggests the existence of other mechanisms for the increased efficacy of pure AEs in inhibiting ERα activity in these cells. In this respect, we have observed that pure AEs strongly induce ERα SUMOylation in the MCF-7 breast cancer cell line, as well as in transiently transfected HEK293 and HepG2 cells ([@bib44]). Abrogating SUMOylation by overexpression of the SENP1 deSUMOylase partially derepressed transcription in the presence of pure AEs in HepG2 cells without an increase in the corresponding activity with estradiol or tamoxifen, suggesting that induction of ERα SUMOylation contributes to pure antiestrogenicity ([@bib44]).

Interestingly, SUMOylation correlated with pure antiestrogenicity in a panel of molecules derived from ICI 164,384. SUMOylation activity was observed with chains harboring 14 carbon atoms, reached maximal levels with chain lengths between 15 and 19 and then diminished with chain lengths of 22 atoms, correlating with inverse agonist activity in HepG2 cells and with the capacity of the AE side chain to interact with the coactivator-binding groove in molecular models ([Fig. 4](#fig4){ref-type="fig"} and [Video 1](#SM1){ref-type="supplementary-material"}). In addition to pure AEs, the SERM raloxifene was shown to induce SUMOylation to a lower degree, correlating with its capacity to suppress basal transcriptional activity in HepG2 cells ([@bib44]). Thus, differential SUMOylation may also contribute to the differential SERM profiles in different tissues.

SUMOylation may affect cofactor recruitment by ERα. Indeed, SUMOylated androgen and glucocorticoid receptors can bind the corepressor DAXX, which in turn recruits chromatin-modifying enzymes (HDACs) or DNA methyltransferases to inhibit transcriptional activity of nuclear receptors ([@bib118]). Another function of SUMOylation is its capacity to recruit SUMO-targeted ubiquitin ligases (STUbLs), such as RNF4 in humans, to promote the degradation of the modified protein, as shown for PML ([@bib41]). There could therefore be a link between SUMOylation of ERα and its increased degradation rate in the presence of SERDs. Indeed, the low level of ERα SUMOylation in the presence of raloxifene ([@bib44]) correlates with the weak induction of degradation by this AE. Studying the modification pattern of ERα in the presence of bazedoxifene and GW7604 would further help assess this hypothesis.

Mass spectrometric analyses led to the identification of four SUMOylation sites in ERα in the presence of ICI 182,780: Lys171 and Lys180 located just upstream of the DBD, Lys299 in the hinge region and Lys472 in the LBD ([Fig. 2A](#fig2){ref-type="fig"}); however, combined mutagenesis of these sites did not abolish the SUMOylation of ERα in the presence of ICI 182,780 ([@bib44]), suggesting that other sites remain to be discovered. Characterization of mutants that inhibit SUMOylation will be important to further investigate the link between SUMOylation and ubiquitination, as well as the role of each type of modification in pure antiestrogenicity.

Impact of ERα mutations found in endocrine treatment-resistant tumors on AE action
==================================================================================

Development of resistance to endocrine treatment is a major outstanding issue for ER+ breast cancer patients. About 25% of ER+ patients with early-stage disease will develop resistance to endocrine treatment within 10 years of diagnosis ([@bib1]), and all metastatic patients will eventually progress on endocrine treatment. Notably, expression of ERα is preserved in the majority of tumors after development of resistance ([@bib57]), suggesting a continued role of ERα in tumor progression. Overexpression of coactivators driving estrogen-dependent transcription is a potential mechanism for this loss of sensitivity, as is activation of signaling pathways that modulate the activity of ERα and/or its coactivators ([@bib57], [@bib92]). Recently, ERα mutations have emerged as an additional mechanism of resistance to hormonal treatment (see [@bib53] for a review). This was first suggested by the isolation of a constitutively active ERα mutant (Y537N) from a breast metastasis ([@bib149]). More recently, several studies have reported the identification of mutations in the ERα LBD in metastases of patients having undergone at least one line of endocrine treatment ([@bib67], [@bib86], [@bib110], [@bib126], [@bib54]). Importantly, these mutations can be detected by isolation of circulating tumor DNA in the blood of breast cancer patients ([@bib38], [@bib114]) and may serve to orient therapeutic decision.

Most mutations characterized in tumors resistant to endocrine therapies are gain-of-function mutations (e.g. E380Q, L536Q/R, D538G and Y537S/C/N) that result in ligand-independent ERα activity in reporter gene assays or on endogenous estrogen target genes (e.g. *GREB1*, *PGR*, *TFF1*, *MYC* and *XBP1*) ([@bib67], [@bib110], [@bib126], [@bib54]). Of interest, several of these mutations or additional ones at the same positions had been previously characterized as leading to increased basal activity in functional analyses of ER signaling ([@bib101], [@bib142], [@bib31]). Constitutive mutants demonstrate increased levels of Ser118 phosphorylation, resistance to HSP90 inhibitor-induced degradation, enhanced recruitment of NCOA family coactivators and/or increased ligand-independent tumor growth in xenograft models compared with wt ERα ([@bib86], [@bib126], [@bib33]). Ligand-independent growth of tumors was also seen in patient-derived xenografts (PDX) established from metastatic ER+ tumors harboring the Y537S mutation ([@bib67]).

Y537S- and D538G-mutant ERα LBDs adopt an agonist-like conformation in the absence of ligand in molecular models and in crystal structures ([@bib93], [@bib86], [@bib126], [@bib33]). As H12 acts as a lid to the ligand-binding cavity in the agonist conformation, its stabilization in this position in the unliganded ERα due to mutations should affect binding of ER ligands including AEs. Indeed, affinity of mutants Y537S and D538G for estradiol and 4-hydroxytamoxifen was 5- to 10-fold smaller than for wt ERα ([@bib33]). Accordingly, higher doses of 4-hydroxytamoxifen and ICI 182,780 were required to inhibit the activity of mutant ERα to levels comparable with those observed with the wt ERα; this may lead to resistance to treatment with AEs in the clinic if concentrations high enough to suppress activity of the mutants cannot be achieved ([@bib86], [@bib126], [@bib54]). In addition, the altered structures of the mutant ERα LBDs in the presence of 4-hydroxytamoxifen ([@bib33]) may lead to different impacts on ER target genes at saturation than with the wt receptor. Finally, it is worth noting that mutation L536A, but not Y537A, was found to increase ERα transcriptional activity and to decrease receptor SUMOylation in the presence of ICI 182,780 ([@bib76], and our unpublished data). It will therefore be of interest in the future to determine to which extent each of the ERα LBD mutations associated with resistance to endocrine therapies affects the efficacy of pure AEs in suppressing ER target gene expression to better guide the choice of second-line therapies.

Conclusion
==========

Structural and functional studies have revealed that AEs use a diversity of conformational solutions to modulate AF2 and/or AF1 activity. This results in varying degrees of antiestrogenicity in breast cancer cells, and in different patterns of tissue-specific activity. How each conformation or change in conformational dynamics is linked to functional effects such as alterations in receptor ubiquitination and SUMOylation, recruitment of specific cofactors, release from DNA and degradation still remains to be further explored. Ultimately, the relevance of these questions to the clinic will be informed by the characterization of orally bioavailable SERDs in both second- and first-line treatment of breast cancer. In addition, recombinant cell lines and PDX models of endocrine therapy resistance due to ERα mutations should prove extremely useful to better characterize the response patterns of each of these ERα mutants to existing AEs and to develop novel, more effective therapeutic molecules or drug combinations.

Declaration of interest
=======================

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding
=======

This work has been funded by the Canadian Institute for Health Research (grant 125863 to SM) and from the Canadian Imperial Bank of Commerce (CIBC) breast cancer research chair at Université de Montréal (to SM).

The authors thank Dr John H White for critical reading of the manuscript.

[^1]: (T Traboulsi and M El Ezzy contributed equally to this work)
